Treatment of pulmonary arterial hypertension and pulmonary arterial hypertension associated with various diseases and daily dosage

摘要

There are treatments or preventions for pulmonary arterial hypertension (PAH) in patients or pulmonary arterial hypertension (APAH) associated with various diseases. This method comprises one or more compound amounts: (S) -ethyl 8-(2-amino-6-((R) -1- (5-chloro-[1,1'-biphenyl]- 2-yl) -2,2,2-trifluoroethoxy) pyrimidin-4-yl) -2,8-diazaspiro [4.5] decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S) -8-(2-Amino-6-((R) -1- (5-chloro- [1,1'-biphenyl] -2-yl) -2,2,2-trifluoroethoxy) pyrimidin-4- Il) -2,8-diazaspiro [4.5] decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the above, comprising systemically administering to the patient a therapeutically effective amount. There are also treatments or prophylaxis for PAH or APAH in patients by systemic administration of about 1 mg / kg / day to about 50 mg / kg / day of therapeutically effective amounts of THP1 inhibitors. There are treatments for PAHs or APAHs in patients at once-daily doses.